Insider Selling: Orchestra BioMed (NASDAQ:OBIO) Insider Sells $61,350.00 in Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider Darren Sherman sold 15,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the sale, the insider owned 1,154,327 shares in the company, valued at approximately $4,721,197.43. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darren Sherman also recently made the following trade(s):

• On Monday, June 1st, Darren Sherman sold 15,000 shares of Orchestra BioMed stock. The shares were sold at an average price of $3.87, for a total value of $58,050.00.

Orchestra BioMed Price Performance

NASDAQ OBIO traded up $0.15 during trading hours on Tuesday, reaching $4.27. 151,794 shares of the stock traded hands, compared to its average volume of 255,775. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. The stock has a 50 day simple moving average of $3.95 and a two-hundred day simple moving average of $4.10. Orchestra BioMed Holdings, Inc. has a 1 year low of $2.20 and a 1 year high of $5.42. The company has a market cap of $255.69 million, a price-to-earnings ratio of -4.40 and a beta of 0.50.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. On average, analysts predict that Orchestra BioMed Holdings, Inc. will post -1.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OBIO. Alyeska Investment Group L.P. purchased a new position in shares of Orchestra BioMed in the third quarter worth $3,386,000. Pathstone Holdings LLC purchased a new stake in Orchestra BioMed during the 3rd quarter valued at $2,495,000. Vanguard Group Inc. boosted its position in Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after buying an additional 324,558 shares during the period. Simplify Asset Management Inc. bought a new stake in Orchestra BioMed in the 1st quarter worth $932,000. Finally, 683 Capital Management LLC purchased a new position in shares of Orchestra BioMed in the fourth quarter valued at about $847,000. Institutional investors own 53.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on OBIO. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Orchestra BioMed in a research note on Thursday, May 14th. B. Riley Financial decreased their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Friday, July 17th. Finally, Barclays lifted their price objective on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.60.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.